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RESEARCH ARTICLE
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Abstract
African Americans have higher rates of asthma prevalence, morbidity, and mortality in com-
parison with other racial groups. We sought to characterize endotypes of childhood asthma
severity in African American patients in an inner-city pediatric asthma population. Baseline
blood neutrophils, blood eosinophils, and 38 serum cytokine levels were measured in a sam-
ple of 235 asthmatic children (6–17 years) enrolled in the NIAID (National Institute of Allergy
and Infectious Diseases)-sponsored Asthma Phenotypes in the Inner City (APIC) study
(ICAC (Inner City Asthma Consortium)-19). Cytokines were quantified using a MILLIPLEX
panel and analyzed on a Luminex analyzer. Patients were classified as Easy-to-Control or
Difficult-to-Control based on the required dose of controller medications over one year of
prospective management. A multivariate variable selection procedure was used to select
cytokines associated with Difficult-to-Control versus Easy-to-Control asthma, adjusting for
age, sex, blood eosinophils, and blood neutrophils. In inner-city African American children,
12 cytokines were significant predictors of Difficult-to-Control asthma (n = 235). CXCL-1, IL-
5, IL-8, and IL-17A were positively associated with Difficult-to-Control asthma, while IL-4
and IL-13 were positively associated with Easy-to-Control asthma. Using likelihood ratio
testing, it was observed that in addition to blood eosinophils and neutrophils, serum cyto-
kines improved the fit of the model. In an inner-city pediatric population, serum cytokines sig-
nificantly contributed to the definition of Difficult-to-Control asthma endotypes in African
American children. Mixed responses characterized by TH2 (IL-5) and TH17-associated
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cytokines were associated with Difficult-to-Control asthma. Collectively, these data may
contribute to risk stratification of Difficult-to-Control asthma in the African American
population.
Introduction
Asthma is a heterogeneous disease comprised of varying clinical, cellular, and molecular phe-
notypes[1]. Cluster analyses of well-characterized asthma cohorts have identified several dis-
tinct clinical phenotypes in adults and children, but they have limited ability to improve
management or guide treatment choices because the phenotypes often overlap and do not nec-
essarily relate to specific underlying pathophysiologic mechanisms[2–4]. Further, although
cluster studies have identified distinct molecular phenotypes of severe asthma, these pheno-
types have not proven to vary by race despite the differing clinical phenotypes. Recently, it has
been suggested that the asthma burden seen in urban US populations may be largely explained
by demographic factors such as race rather than by environmental factors secondary to living
in an urban location[5, 6]. Accordingly, a comparable prevalence of asthma was found in
urban and rural populations of African Americans teenagers[7]. African Americans have
higher rates of asthma prevalence, morbidity, and mortality in comparison with other racial
groups in America[8–10]. It has been suggested that this racial disparity cannot be explained
solely by socioeconomic or environmental factors with black race being reported as an inde-
pendent risk factor for asthma[11, 12]. Collectively, these findings suggest that immunologic
profiles that characterize asthma in African Americans may predispose to more severe or diffi-
cult to control phenotypes. Interestingly, higher TH17 activation was reported in Asians versus
European Americans with atopic dermatitis, suggesting a racial difference in immunologic
mechanisms of disease[13].
The Asthma Phenotypes in Children (APIC) Study, which was conducted by the NIAID-
funded Inner City Asthma Consortium, offered us an opportunity to specifically characterize
asthma immunophenotypes in African American children as 64% of APIC participants are
African American. Towards this goal, we characterized serum cytokine profiles in a subset of
235 children out of the 717 children (33%) enrolled in APIC. Our findings indicate that serum
cytokine concentrations, in addition to blood neutrophils and eosinophils, may be helpful in
defining Difficult-to-Control asthma endotypes in African American inner-city children.
Methods
Study population
IRB approval was obtained from the following institutions: Johns Hopkins University School
of Medicine, Department of Pediatrics, Baltimore, MD; Boston University School of Medicine,
Boston, MA; Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL; Cincinnati
Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cin-
cinnati, OH; University of Texas Southwestern Medical Center, Dallas, TX; National Jewish
Health, Denver, CO, and Children’s Hospital Colorado and University of Colorado School of
Medicine, Aurora, CO; Henry Ford Health System, Detroit, MI; College of Physicians and Sur-
geons, Columbia University, New York, NY; and Children’s National Health System, Wash-
ington, DC. Written informed consent was obtained from the parent or legal guardian of
each child. The subjects included in this study were enrolled in the APIC Study which is an
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epidemiologic, multi-center, longitudinal study designed to define phenotypic characteristics
of Difficult-to-Control asthma among children receiving one year of guideline-based therapy
for asthma and rhinitis/rhinosinusitis. A detailed description of study methods including
recruitment, enrollment, and data collection (skin testing, spirometry, and exhaled nitric
oxide) is described in the primary manuscript for the APIC study[14]. Seven hundred and sev-
enteen subjects from 9 clinical sites (Baltimore MD, Boston MA, Chicago IL, Cincinnati OH,
Dallas TX, Denver CO, Detroit MI, New York NY, Washington DC) were enrolled in APIC.
Study approval was granted by each center’s Institutional Review Board. Enrolled children
were between the ages of 6 to 17 years with physician-diagnosed asthma. Participants were
required to report 2 or more episodes of short-acting beta-agonist administration within the
12 months prior to the screening visit (exclusive of exercise-induced symptom use), have
insurance coverage, and reside in a pre-selected urban recruitment census to qualify for entry
into the study. Only participants who identified as non-Hispanic African American were
included in this analysis and 235 subjects were enrolled as suggested by sample size calcula-
tions necessary for statistical power of at least 90% based on our previously published results
[15]. Comparative data for other races were not included because, of the remaining 129 sub-
jects, only 6 subjects were non-Hispanic white, 17 were of other or mixed race, and 106 were
Hispanic with race unidentified.
Protocol-defined asthma and rhinitis management was started at the time of screening.
Asthma and rhinitis treatment algorithms were based on the NAEPP Expert Panel Report-3
(EPR-3) and the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines[16, 17]. Based on
study treatment guidelines for asthma and rhinitis, patients were provided with prescribed
medications (Flovent1 Diskus1 (fluticasone), Advair™ Diskus (fluticasone propionate, sal-
meterol), Ventolin1 HFA (albuterol), Flonase1 Nasal Spray (fluticasone), cetirizine, monte-
lukast). Demonstration of medication adherence was required for study enrollment and was
assessed at the enrollment visit following a 4-week run-in period. Subsequently, asthma con-
trol was evaluated at 6 clinical study visits at 2-month intervals at which time clinicians pre-
scribed medications based on the level of asthma control and medication compliance over the
previous two months. Asthma control was assessed based on asthma symptoms, albuterol use,
use of systemic corticosteroids, FEV1 (forced expiratory volume), and current asthma therapy.
Classification of subjects occurred following the last study visit. Participants requiring 50
mcg twice daily of fluticasone, montelukast only, or needing no controller medication at four
or more of the six post-baseline study visits, were classified as having Easy-to-Control asthma.
Children requiring 250 mcg twice daily of fluticasone at four or more of six post-baseline
study visits were classified as Difficult-to-Control asthma. Children who did not fall into either
classification were considered indeterminate and were not included in the analysis.
Of the 717 subjects enrolled in APIC, 510 randomly selected subjects had blood analyzed
for cytokines. Of these 510 subjects, 502 had complete data for demographics, blood eosino-
phils, blood neutrophils, and serum cytokines. Less than 4 baseline visits were done in 38
patients and an additional 100 patients were excluded from our analysis as their treatment clas-
sification was indeterminate. Out of these 364 subjects, 235 were African American, of which
108 subjects were classified as Easy-to-Control and 127 subjects were classified as Difficult-to-
Control.
Blood collection and analysis
Whole blood was collected by venipuncture at the enrollment visit. Blood for cytokine analysis
was collected into serum separator tubes and centrifuged and aliquoted into cryovials follow-
ing a standard protocol during or immediately following the study visit. Serum aliquots were
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frozen and stored at -80˚C pending shipment to the biorepository and subsequently to the ana-
lyzing laboratory. As freeze-thaw cycles can alter cytokine measures, samples in our analysis
were not freeze-thawed[18]. Total numbers of eosinophils and neutrophils were determined
by the product of the differential and total cell count. Using 25 μL of participant serum, cyto-
kines were quantified according to the manufacturer’s instructions using a premixed 38 Plex
MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel (Millipore Corpora-
tion, Billerica, MA) and analyzed on a Luminex 100/200 analyzer (BioRad, Hercules, CA).
Serum cytokine concentrations were determined using Bio-plex 6.1 software (BioRad, Hercu-
les, CA). A similar approach for analyzing cytokines in BAL (bronchoalveolar lavage) fluid
from asthmatics has been used previously[19]. Cytokines included in the analysis are listed in
S1 Table.
Statistical analysis
As shown in S1 Fig, cytokine replicate pairs had a good agreement and were averaged to pro-
duce a single result for analysis. Cytokine values were skewed based on a diagnostic plot (S2
Fig) and the result of a Shapiro-Wilk test and were, therefore, log-transformed for statistical
tests and models. For analysis purposes, results below detection were assigned a value of the
lower limit of detection divided by the square root of 2, and results above detection were
assigned a value equal to the upper limit of detection[20].Overall, 22% of cytokine values were
below the lower limit of detection and 2% were above the upper limit of detection. The per-
centage of values above the lower limit of detection by inflammatory marker is displayed in S1
Table and S2 Fig.
To compare differences in baseline characteristics and demographics between Difficult-to-
Control and Easy-to-Control asthma, chi-square or Fisher exact tests were used for categorical
variables, and t-tests or Wilcoxon tests were used for normally distributed and non-normally
distributed continuous variables, respectively. Normality of baseline characteristics and demo-
graphics was determined by assessing the skewness of variables. Univariate logistic regression
was used to estimate the association with Difficult-to-Control asthma for blood eosinophils,
neutrophils, and each of the 38 cytokines. Due to the exploratory nature of the analysis, no
attempts were made to adjust for multiple comparisons.
Logistic models were fit using Difficult-to-Control versus Easy-to-Control as the outcome
and demographics, blood eosinophils, blood neutrophils, and/or cytokines as covariates.
Nested models were compared using likelihood ratio testing, which compares the goodness of
fit of two models. The glmnet procedure was used to fit a multiple logistic regression model
with an elastic-net penalty, which is a combination of lasso and ridge regression penalties. This
technique is particularly efficient for feature selection in data with collinearity and/or many
features, in order to select the most relevant cytokines for distinguishing Easy-to-Control ver-
sus Difficult-to-Control asthma after adjusting for age, sex, blood eosinophils, and blood neu-
trophils[21, 22]. Adjustments were performed by including the listed variables in the model, so
that the relationships between cytokines and Difficult-to-control asthma were free of con-
founding. Repeated 10-fold cross validation was used to prevent overfitting and select the best
penalty parameters. R version 3.3.3 was used for analyses.
Results
Demographic and baseline characteristics of study population
The African American children included in this study were a randomly selected subset of sub-
jects in the APIC study conducted by the Inner City Asthma Consortium (ICAC)[14]. Demo-
graphic data from the 235 children comprising our study subset were compared to the entire
Endotypes of difficult to control asthma
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African American APIC population (N = 311) and no significant differences were observed
(data included in S2 Table). Demographic features and baseline characteristics were compared
between the Difficult-to-Control and Easy-to-Control populations in our analysis population
(Table 1). When compared to Easy-to-Control, Difficult-to-Control participants reported use
of more asthma controller medications (p<0.001), had higher rates of oral corticosteroid
courses for asthma (p<0.0001), higher total serum IgE (p = 0.004), and lower FEV1 (p<0.001)
and FEV1/FVC (p<0.001) at study entry. Difficult-to-Control participants were more likely to
have allergic rhinitis (p<0.001) as well as aeroallergen (p = 0.005) sensitization at study entry.
No differences were observed between the Easy-to-Control and Difficult-to-Control groups
with regards to sex, age, income, BMI (body mass index) percentile, family history of asthma,
age at asthma diagnosis, personal diagnosis of eczema, asthma-related hospitalizations, FeNO
(fractional exhaled nitric oxide), or food sensitization.
Blood concentrations of eosinophils and neutrophils differ by treatment
classification
Children with Difficult-to-Control asthma had higher numbers of blood eosinophils (p = 0.02)
and neutrophils (p = 0.02) (Table 2) when compared to children with Easy-to-Control asthma.
There was no correlation between eosinophil and neutrophil counts. The probability of Diffi-
cult-to-Control asthma was greater as blood eosinophil and neutrophil concentrations
increased (Fig 1). Since systemic corticosteroids can alter blood neutrophil and eosinophil
counts, we examined corticosteroid use among participants. Seven percent of subjects received
an oral corticosteroid course in the month prior to their blood draw. Receiving an oral cortico-
steroid course in the month prior to the blood draw was not associated with significantly ele-
vated or lower neutrophil
Serum cytokine concentrations differ by treatment classification
IL-12p40 (p = 0.005), IL-13 (p = 0.04), IL-1β (p = 0.02), and IL-4 (p = 0.03) were increased in
those with Easy-to-Control asthma (Table 3). No cytokines were positively associated with Dif-
ficult-to-Control asthma. A multivariate feature selection procedure was used to determine
which cytokines were most predictive of Difficult-to-Control versus Easy-to-Control asthma
(Table 4). IL-5, IFN-γ (interferon gamma) and TH17 (CXCL-1, IL-17A, IL-8) associated cyto-
kines were positively associated with Difficult-to-Control asthma; while EGF (epidermal
growth factor), eotaxin, IL-lβ, IL-4, IL-12p40, IL-13, and MDC (macrophage-derived chemo-
kine) were positively associated with Easy-to-Control asthma.
Definition of Difficult-to-Control childhood asthma endotypes using blood
eosinophils, neutrophils, and serum cytokines
To ascertain whether cytokines bring added value to the definition of the Difficult-to-Control
childhood asthma endotype in our African American cohort, models with the outcome of Dif-
ficult-to-Control asthma were compared using likelihood ratio tests (Table 5). Age, sex, blood
eosinophils, and neutrophils, and/or selected serum cytokines were included in all models.
Cytokines selected by the multivariate feature selection procedure were the only cytokines
included in the models. The model including only demographics was not significantly differ-
ent than the null model. The addition of blood eosinophils and neutrophils significantly
improved the fit of the model (p = 0.006). The addition of selected cytokines further improved
the fit of the model when compared to the model containing only demographics and blood
eosinophils and neutrophils (p<0.001). Thus the addition of CXCL-1, IFN-γ, IL-5, IL-17A,
Endotypes of difficult to control asthma
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Table 1. Participant characteristics and demographics1,2.
Characteristic Difficult-to-Control
(N = 127)
Easy-to-Control
(N = 108)
P-value
Sex—Male 67 (52.8%) 64 (59.3%) 0.39
Age (years) 11.1 (3.0) 11.0 (2.9) 0.91
BMI percentile3 89.0 [64.8; 98.7] 87.9 [56.5; 97.2] 0.13
Income <$15,000 63 (50.0%) 56 (51.9%) 0.88
Family history of asthma 98 (78.4%) 74 (70.5%) 0.22
Eczema diagnosis 83 (65.4%) 63 (58.3%) 0.33
Allergic rhinitis diagnosis 102 (80.3%) 63 (58.3%) <0.001
Asthma medical history
Age at asthma diagnosis (months) 3 24.0 [10.5; 60.0] 24.0 [12.0; 66.0] 0.09
Controller treatment step 4.7 (1.5) 1.8 (1.5) <0.001
Any hospitalizations (in previous year) 26 (20.5%) 9 (8.3%) 0.02
Any steroid courses4 (in previous year) 83 (65.4%) 33 (30.6%) <0.001
FeNO (ppb)3,5 24.5 [12.0; 40.0] 19.0 [11.9; 34.5] 0.17
FEV1 (% predicted) 87.3 (17.9) 97.4 (15.9) <0.001
FEV1/FVC (% predicted) 73.3 (11.0) 79.5 (8.4) <0.001
Total serum IgE (kU/L)3,5 412.5 [106.8; 957.5] 185.5 [61.0; 576.2] 0.004
Number of allergen sensitizations6 10.2 (6.2) 8.1 (6.1) 0.008
Number of aeroallergen sensitizations7 9.5 (5.6) 7.4 (5.6) 0.005
Sensitized to foods8 35 (27.8%) 36 (33.6%) 0.41
1. Unless otherwise noted, characteristics are compared using chi-square or Fisher’s exact test for categorical variables, and ANOVA or t-test for
continuous variables.
2. Unless otherwise noted, summary statistics are frequency (%) for categorical variables and mean and standard deviation for continuous variables.
Unless otherwise noted, data was obtained at screening visit.
3. Summarized using the median and inter-quartile range and tested using a Wilcoxon test.
4. Defined as having at least one outpatient oral steroid course or hospitalization.
5. Obtained at the time of enrollment visit.
6. Sensitization is based on a positive skin prick test and/or positive specific IgE (0.35 kUA/L) to at least one of the following allergens: Alternaria tenuis
(skin prick test) or Alternaria alternata (specific IgE), Aspergillus fumigatus (both skin prick test and specific IgE), Cladosporium herbarum (specific IgE
only), Dermatophagoides farinae, Dermatophagoides pteronyssinus, German cockroach, American cockroach, mouse, rat, cat, dog, oak, pecan, birch,
maple, Eastern 8 tree mix, ragweed mix (giant/short; skin prick test) or short ragweed (specific IgE), timothy grass, Kentucky Blue/June, Orchard and
Timothy (K-O-T) grass mix, peanut, egg and milk.
7. Sensitization is based on a positive skin prick test and/or positive specific IgE (0.35 kUA/L) to at least one of the following allergens: Cladosporium
herbarum (specific IgE only), Dermatophagoides farinae, Dermatophagoides pteronyssinus, German cockroach, American cockroach, mouse, rat, cat, dog,
oak, pecan, birch, maple, Eastern 8 tree mix, ragweed mix (giant/short; skin prick test) or short ragweed (specific IgE), timothy grass, Kentucky Blue/June,
and Orchard and Timothy (K-O-T) grass mix.
8. Sensitization is based on a positive Fx5 multitest which includes specific IgE testing to the following allergens: wheat, egg, milk, soy, peanut, and fish.
https://doi.org/10.1371/journal.pone.0180778.t001
Table 2. Concentrations of blood eosinophils and neutrophils by treatment classification1.
Granulocyte Difficult-to-Control
(n = 127)
Easy-to-Control
(n = 108)
OR [95% CI]2 P-value3
Eosinophils/μL 351 (252) 278 (210) 1.43 (1.07, 1.95) 0.02
Neutrophils/μL 3248 (1998) 2712 (1437) 1.40 (1.06, 1.91) 0.02
1. Numbers shown for Difficult-to-Control and Easy-to-Control are Mean (SD).
2. OR = odds ratio associated with a 1-interquartile range change; CI = confidence interval.
3. P-value based on t-test.
https://doi.org/10.1371/journal.pone.0180778.t002
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EGF, eotaxin, IL-lβ, IL-4, IL-12p40, IL-13, and MDC serum concentrations to blood eosino-
phils and neutrophils adds significant value to the definition of the Difficult-to-Control asthma
endotype.
Discussion
Despite the strong racial disparities observed in asthma morbidity, previous studies have not
characterized immunophenotypes of Difficult-to-Control asthma in African American chil-
dren[23, 24]. We found that although blood eosinophils and neutrophils were useful biomark-
ers of Difficult-to-Control asthma, serum cytokines significantly enhanced the definition of
Difficult-to-Control asthma. Mixed responses characterized by IL-5 and IL-17 upregulation
were associated with Difficult-to-Control disease while IL-4 and IL-13 were associated with
Easy-to-Control asthma. This data may contribute to the ability to risk stratify this population
of Difficult-to-Control asthmatics. These findings may have important treatment implications
as they suggest consideration of the use of biologics to target multiple inflammatory pathways
in African American children with Difficult-to-Control asthma.
Increased eosinophils or neutrophils have been reported in sputum of severe and poorly
controlled asthmatics[25, 26] and increased blood neutrophils and eosinophils have been asso-
ciated with severe asthma in children[27]. Similarly, we found increased blood neutrophils
and eosinophils in the Difficult-to-Control population.
Fig 1. Probability of difficult-to-control asthma rises as blood eosinophil and neutrophil concentrations increase. Graphical
representation of blood eosinophil and neutrophil concentrations and the probability of Difficult-to-Control asthma. Values from all 235
subjects in the analysis are included. The blood neutrophil and eosinophil counts were not correlated in this population (Pearson
correlation = 0.11, p = 0.11).
https://doi.org/10.1371/journal.pone.0180778.g001
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Difficult-to-Control asthma was positively associated with cytokines/chemokines (CXCL-1,
IL-17A, and IL-8) previously described to be associated with neutrophilic inflammation. Asso-
ciation of increased IL-8 with severe asthma has previously been reported in adults and chil-
dren[19, 26, 28]. Previous analysis of airway secretion samples from predominantly African
Table 3. Serum concentrations of 38 cytokines by treatment classification1.
Cytokine (pg/mL) Difficult-to-Control
(n = 127)
Easy-to-Control
(n = 108)
OR [95% CI]2 P-value3
CXCL-1 2129.8 (1.5) 1931.0 (1.6) 2.99 (0.81, 11.4) 0.10
EGF 92.8 (3.2) 108.3 (3.0) 0.76 (0.45, 1.28) 0.30
EOTAXIN 61.9 (1.8) 68.5 (1.7) 0.46 (0.15, 1.36) 0.16
FGF2 58.0 (1.8) 61.6 (2.0) 0.71 (0.28, 1.79) 0.47
FLT3L 9.5 (3.8) 10.4 (3.5) 0.88 (0.56, 1.40) 0.60
FRACTALKINE 101.3 (3.0) 96.3 (2.3) 1.13 (0.62, 2.08) 0.70
GCSF 40.7 (2.2) 40.4 (2.4) 1.03 (0.50, 2.12) 0.94
GMCSF 25.9 (2.0) 28.7 (2.2) 0.65 (0.29, 1.43) 0.29
IFNALPHA2 43.9 (2.9) 46.2 (2.7) 0.89 (0.50, 1.59) 0.70
IFNGAMMA 14.6 (4.9) 12.8 (4.7) 1.14 (0.78, 1.66) 0.51
IL10 2.6 (3.7) 3.6 (5.2) 0.71 (0.47, 1.07) 0.10
IL12P40 12.6 (3.2) 20.1 (3.6) 0.49 (0.29, 0.79) 0.005
IL12P70 3.3 (4.4) 3.7 (5.9) 0.90 (0.63, 1.30) 0.59
IL13 4.1 (5.9) 6.9 (7.1) 0.71 (0.51, 0.97) 0.04
IL15 1.6 (2.7) 2.1 (3.2) 0.61 (0.35, 1.05) 0.08
IL17A 5.8 (6.0) 4.4 (5.9) 1.22 (0.87, 1.71) 0.25
IL1ALPHA 17.9 (3.8) 21.7 (4.1) 0.79 (0.51, 1.22) 0.28
IL1BETA 1.1 (2.8) 1.6 (3.7) 0.55 (0.32, 0.91) 0.02
IL1RA 69.8 (2.8) 76.1 (2.6) 0.82 (0.45, 1.48) 0.51
IL2 2.0 (3.7) 2.7 (4.2) 0.71 (0.46, 1.10) 0.12
IL3 0.6 (1.5) 0.6 (1.6) 0.33 (0.07, 1.32) 0.13
IL4 5.1 (3.1) 7.5 (4.4) 0.60 (0.37, 0.95) 0.03
IL5 1.0 (3.4) 0.9 (3.5) 1.33 (0.82, 2.22) 0.25
IL6 2.7 (5.6) 3.6 (7.2) 0.81 (0.59, 1.12) 0.20
IL7 6.4 (3.0) 6.5 (3.4) 0.98 (0.58, 1.64) 0.93
IL8 22.1 (3.4) 18.5 (3.2) 1.34 (0.81, 2.24) 0.26
IL9 1.7 (2.8) 1.8 (2.5) 0.98 (0.53, 1.81) 0.94
IP10 301.3 (1.7) 315.8 (1.8) 0.71 (0.25, 2.04) 0.52
MCP1 396.7 (1.7) 390.2 (1.7) 1.16 (0.36, 3.78) 0.81
MCP3 18.4 (2.6) 21.7 (2.5) 0.66 (0.35, 1.23) 0.19
MDC 1893.9 (1.5) 1988.8 (1.4) 0.43 (0.07, 2.16) 0.32
MIP1ALPHA 18.8 (4.0) 18.8 (3.7) 1.00 (0.65, 1.56) >0.99
MIP1BETA 50.8 (2.0) 51.0 (1.9) 0.98 (0.40, 2.39) 0.96
SCD40L 9321.5 (1.3) 8952.1 (1.5) 2.18 (0.39, 14.0) 0.38
TGFALPHA 2.8 (3.1) 2.4 (3.1) 1.40 (0.83, 2.39) 0.21
TNFALPHA 11.3 (2.0) 11.2 (2.3) 1.02 (0.46, 2.23) 0.96
TNFBETA 3.5 (5.2) 5.3 (5.8) 0.72 (0.51, 1.03) 0.07
VEGF 268.8 (2.3) 279.9 (2.4) 0.87 (0.43, 1.78) 0.71
1. Numbers shown for Difficult-to-Control and Easy-to-Control are Geometric Mean (Geometric SD).
2. OR = odds ratio associated with a 1-log10 unit change; CI = confidence interval.
3. P-value based on t-test.
https://doi.org/10.1371/journal.pone.0180778.t003
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American children with asthma showed that, in addition to other cytokines and chemokines,
Differential CXCL-1 and IL-8 concentrations characterized severe compared to moderate
asthma[19]. Increased IL-17A has been implicated in severe asthma by prior studies[29, 30].
Traditionally, TH2-associated inflammation has been implicated in the pathogenesis of
asthma [31]. In our study, IL-4 and IL-13 were positively associated with Easy-to-Control
asthma. Primarily TH2-associated asthma is generally glucocorticoid responsive, while TH2/
TH17 predominant asthma may be resistant to corticosteroid treatment[32, 33]. In our popula-
tion, Difficult-to-Control asthma was positively associated with a combination of TH2 and
TH17-associated inflammatory markers. TH17 inflammation has been associated with neutro-
philic inflammation and corticosteroid unresponsive asthma[30, 34]. Recent data from our
group and others suggests that this may actually be due to a unique population of cells that co-
produce TH2 and TH17 cytokines[15, 33, 35]. Brandt et al. reported the presence of IL-13+IL-
17A+ double producing T-cells in the lungs of mice co-exposed to house dust mite and diesel
exhaust particles[35]. Studies have implicated dual-positive TH2/TH17 cells in steroid resistant
asthma. Irvin et al. analyzed the infiltrating T helper cells in the BAL fluid from asthmatic
patients and assessed their response to steroid treatment in vitro[33]. They found that dual-
positive TH2/TH17 (IL-4+/IL-17+) cells and IL-17A were present at a higher frequency in the
BALF from steroid-resistant asthmatic patients. These TH2/TH17 cells were resistant to DEX
(dexamethasone)-induced cell death during an in vitro incubation and the TH2/TH17 predom-
inant subgroup of patients manifested the most severe form of asthma[33]. We found an asso-
ciation between IL-17 and IL-5 with difficult-to-control asthma, in comparison to previous
studies which report IL-4+IL-17+ or IL-13IL-17+ T-cell populations. TH2 cells are classically
regarded as a homogenous population, however, multiple recent studies have challenged this
notion. Notably, the only partial overlap between IL-4+ and IL-5+ cells was observed in CD4
+163- cells from BAL of asthmatics in the study by Irvin et al. This suggests there is some
degree of nonsynchronous production of TH2 cytokines in T-cell populations, which may in
part explain our TH2-asscoiated cytokine findings. Further, pathogenic IL-5+ TH2 cells have
been shown to be central to the development of eosinophilic airway inflammation and possess
a greater ability to promote inflammation[36].
We were unable to compare immunophenotypes between racial groups as the APIC popu-
lation is 64% African American with the remainder of the population being racially heteroge-
neous. However, analysis of a smaller and heterogeneous population of non-African American
in the APIC study showed a differing cytokine profile, which urges consideration of whether
Difficult-to-Control asthma phenotypes differ by race. Further validation of these findings in
Table 4. Inflammatory mediators associated with asthma control based on multivariate feature
selection.
Selected Inflammatory Mediators
(direction of association with Difficult-to-Control asthma)1
TH17 associated TH2 associated Non TH2 or TH17
associated
• CXCL-1 (+)
• IL-8 (+)
• IL-17A (+)
• IL-4 (-)
• IL-5 (+)
• IL-13 (-)
• EGF (-)
• Eotaxin (-)
• IFN-γ (+)
• IL-1β (-)
• IL-12p40 (-)
• MDC (-)
1. + denotes cytokines associated with Difficult-to-Control disease,—denotes cytokines associated with
Easy-to-Control asthma.
https://doi.org/10.1371/journal.pone.0180778.t004
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another cohort and comparison to a non-African American comparison group should be pur-
sued. Previous reports have shown that the effect sizes of genetic variants which relate to
asthma significantly differ between non-European and European populations[37]. Notably,
racial differences in TH2/TH17 inflammatory pathways have been reported in atopic dermatitis
whereby Asian patients had a higher induction of TH17 /TH22-associated cytokines compared
to patients of European ancestry[13].
In this study, we focused on African Americans, however, data from 129 non-African
American APIC subjects were analyzed using the same statistical procedures. The racial het-
erogeneity and small size of this population in comparison to the African American population
limited the reliability of this data, which was not included in the manuscript for this reason.
However, it is interesting to note that a different cytokine profile was identified in the non-
African American population. IL-1RA was positively associated with Difficult-to-Control dis-
ease and IL-5 was positively associated with Easy-to-Control asthma.
Our study has several unique strengths. These include features inherent to the APIC study
from which the patients were enrolled. APIC enrolled inner-city children, a population dispro-
portionately affected by asthma morbidity and mortality[38]. Since the majority of APIC study
participants were African American, we were positioned to characterize inflammatory profiles
in at-risk African American children with asthma. APIC is a multi-center, longitudinal study,
which allowed for a prospective evaluation over an entire year, designed to assess numerous
parameters to identify factors that promote Difficult-to-Control asthma. APIC subjects
received standardized, algorithm-based management of asthma and allergic rhinitis for one
year. Further, peripheral blood characterization was obtained at baseline, which allows consid-
eration for validation of this method to be used as a predictive model for assessing asthma con-
trol in a clinical setting. Additionally, blood samples are more likely to reflect systemic
inflammation than bronchial biopsies or washings and have been previously reported to be
associated with airway inflammation, asthma phenotype, and asthma severity[39, 40].
Table 5. In addition to demographics and blood eosinophils and neutrophils, serum cytokines strengthen the characterization of difficult-to-con-
trol asthma.1,2.
Model Variables Comparison Area Under the Curve
(95% CI)
P-value3
M0 Null model — — —
M1 Demographics4 vs. M0 0.53 (0.45, 0.60) 0.61
M2 Demographics
+ eosinophils/neutrophils
vs. M1 0.62 (0.55, 0.69) 0.006
M3 Demographics
+ eosinophils/neutrophils
+ selected cytokines5
vs. M2 0.75 (0.69, 0.81) <0.001
1. Models including demographics, blood eosinophils, and neutrophils, and/or selected serum cytokines with the outcome of Difficult-to-Control asthma
were compared using likelihood ratios.
2. Additional results not shown in table
A) Model with selected cytokines only: AUC = 0.71 (95% CI: 0.64, 0.77)
B) Model with demographics + selected cytokines: AUC = 0.71 (95% CI: 0.64, 0.78).
C) In a test of the model with demographics + selected cytokines versus the model with demographics only (M1 in the table), the resulting p-value was
0.001.
3. P-value based on likelihood ratio test.
4. Demographics include age and sex.
5. Selected cytokines included only cytokines selected by the multivariate feature selection procedure (CXCL-1, IL-8, IFN-γ, IL-5, IL-17A, EGF, eotaxin, IL-
lβ, IL-4, IL-12p40, IL-13, and MDC).
https://doi.org/10.1371/journal.pone.0180778.t005
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Our study also has some important limitations. We cannot control for the potential effects
of inhaled or oral corticosteroids on the concentrations of chemokines, cytokines, and granu-
locytes observed in our study. Seven percent of subjects in our population were on an oral
corticosteroid in the month prior to their blood draw. We did not see any impact of oral corti-
costeroids on blood neutrophils or eosinophils in this subset and oral corticosteroids are more
likely to alter blood granulocytes than inhaled corticosteroids in the month prior to their
blood draw. Furthermore, use of blood samples for testing for granulocyte and inflammatory
mediators, as in our study, would, in theory, be less susceptible to the effects of inhaled cortico-
steroids when compared to studies utilizing samples obtained from the airways (sputum, BAL,
bronchial tissue). A previous study showed no association between the use of inhaled cortico-
steroids and sputum neutrophil percentage[24]. Also, Hastie et al. reported no significant
effect of inhaled corticosteroid use on sputum cell counts or inflammatory mediator levels[41].
Additionally, as is true with other studies assessing cytokines, cytokine concentrations are
relatively low which can lead to difficulty in detection. Percent of values above the lower limit
of detection for cytokines measured in the study are included in S1 Table and are comparable
to levels seen in other studies. Our analysis did not account for potential confounders which
may have impacted specific cytokine values such as season in which blood was drawn and the
presence of acute respiratory infection. However, the degree of influence that season has on
inflammatory cells and cytokines is unclear with previous research suggesting there was no
alteration in TH17 and TH1 responses during pollen season in patients with allergic respiratory
disease[42]. Also, due to the exploratory nature of this analysis, we did not adjust for multiplic-
ity in the univariate tests shown in Table 3. Although we acknowledge that the resulting p-val-
ues insufficiently control for type I error (false positives), they have minimal contribution to
the main analysis, which is the prediction model. We feel that the methodology used for build-
ing the prediction model adequately addresses the issue of multiplicity. Finally, as we measured
serum cytokine concentrations and did not isolate and phenotype T-cells, we cannot defini-
tively prove that the cytokines were secreted from TH-cells as opposed to other immune cells.
The need for risk stratification, refinement of the definition of asthma endotypes, and novel
therapeutic agents that target the biological mechanisms underlying the severe asthma pheno-
type has been highlighted by experts[43]. Results of this study can be used in conjunction with
other research to improve risk stratification in this asthmatic population. The data herein urge
the consideration of using multiple biologic treatments for Difficult-to-Control asthma in
African American children. Given the association of IL-17A and IL-5 with Difficult-to-Control
asthma in African American children in our inner-city population, therapeutics targeting IL-
17 and IL-5 should be considered. A trial of brodalumab, a human anti–IL-17 receptor A
monoclonal antibody, in poorly controlled moderate to severe asthmatics did not show signifi-
cant improvement in primary or secondary endpoints[44]. However, it may show efficacy in a
trial of African American asthmatics with elevated serum IL-17. Further, our data suggest that
anti-IL-5 may be most effective in African Americans. Targeting both TH2 and TH17 associ-
ated pathways of inflammation has been suggested previously given the concern that isolated
targeting of TH2 cytokines may promote TH17-associated corticosteroid resistant neutrophilic
airway inflammation[45, 46]. Furthermore, combined targeting of TH2 and TH17 inflamma-
tion has been suggested based on race in treatment of atopic dermatitis[13].
In summary, we have identified systemic cellular and cytokine/chemokine inflammatory
profiles among inner-city African American children with Easy-to-Control and Difficult-to-
Control asthma. Our study highlights the need to consider targeting multiple inflammatory
pathways in the treatment of Difficult-to-Control pediatric asthma in the African American
population.
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Supporting information
S1 Table. Mean, lower limit of detection, and proportion of values above the lower limit of
detection, overall and by inflammatory marker.
(DOCX)
S2 Table. Comparison of African American subjects in the full APIC study population and
the cytokine subsample.
(DOCX)
S1 Fig. Replicate agreement by inflammatory marker. Scatter plot of replicate A versus repli-
cate B. Each panel represents a different cytokine, and each circle represents a pair of replicate
values. The forty-five-degree line through the origin represents perfect agreement. Annotated
values are the concordance coefficient correlation and associated 95% confidence interval.
(TIF)
S2 Fig. Cytokine distributions and proportion of cytokines above the lower limit of detec-
tion. Left and middle panels display the distribution of values on the original scale and a log-
10 scale, respectively. The spread of values is represented by boxplots, where the black dot rep-
resents the median, the gray box represents the interquartile range, the whiskers extend to 1.5
times the interquartile range, and individual tick marks represent data points beyond the
1.5IQR threshold. Right panel contains the percentage of values above the lower limit of
detection.
(TIF)
S3 Fig. Result of feature selection procedure. Each line represents one of the 38 inflamma-
tory markers. A non-zero beta coefficient (y-axis) represents statistical significance. As lambda
grows (x-axis moves to the right), the penalty on the coefficients increases, driving irrelevant
predictors to zero. Lines are truncated at the optimal lambda selected by repeated cross-valida-
tion (-2.97). At this level, 12 significant cytokines remain. Line color represents association
with Difficult-to-Control (red = negative, blue = positive).
(TIF)
S1 File. Zip file of analysis data and metadata. The CSV file (anly_cyto_share.csv) contains
the core data for the analysis population of N = 235. The structure of the data is 1 record per
participant per cytokine. The corresponding PDF file (anly_cyto_share.pdf) contains meta-
data, including names, labels, and distributions of each variable.
(ZIP)
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